Immune cell therapy for relapsed neurological autoimmune diseases
Treatments studied
Part of Brain & nervous system, Cancer, Eyes & vision, Immune system & allergy clinical trials.
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a neurological autoimmune disease like neuromyelitis optica, myasthenia gravis, multiple sclerosis, autoimmune encephalitis, or chronic inflammatory demyelinating polyneuropathy that has relapsed or is not responding to treatment.
- Your blood tests show that your B cells have CD19 or BCMA proteins on them.
- If you can become pregnant or get someone pregnant, you must use birth control during the study and for 6 months after treatment.
- You are willing to follow the study procedures and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new type of immune cell therapy (CAR T-cells) against several relapsed or hard-to-treat autoimmune diseases that affect the nervous system. The goal is to see if this treatment can safely calm the immune system and improve symptoms.
This trial tests a universal CAR-T cell treatment for people with autoimmune diseases of the nervous system that haven't responded to standard therapies. It aims to see if this therapy can help control diseases like neuromyelitis optica, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and multiple sclerosis.
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
This trial tests a new cell therapy called C-CAR168 for people with autoimmune diseases affecting the brain and spinal cord, such as multiple sclerosis, neuromyelitis optica, autoimmune encephalitis, or stiff person spectrum disorder. It is for patients whose condition has not improved with standard treatments.
This trial tests a new treatment using UCAR T-cells that target CD19 and BCMA proteins, for people with autoimmune diseases like lupus or arthritis that have come back or not responded to other treatments. It aims to see if this therapy can help control the disease.
Hear when a new Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.